Vical, Inc. (NASDAQ:VICL) applies its patented DNA delivery technologies and other therapeutic approaches to develop biopharmaceutical products for the prevention and treatment of chronic or life-threatening infectious diseases. Headquartered in San Diego, California, Vical is independently pioneering the development of paradigm-changing therapies, and is partnering with such industry leaders as Astellas, AnGes, Bristol-Myers Squibb, and Merial. For more information, visit the company’s website at www.vical.com